Insider · SEC Form 4 filer
Sarah Nemec
Companies
Where they file as an insider
Bolt Biotherapeutics (BOLT) Senior VP, Finance and PAO Latest filing Sep 18, 2026
Track record
Did their buys beat the typical stock?
Open-market buys5
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check1
Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.
Bolt Biotherapeutics (BOLT) Bought Jun 5, 2026 · $1.97K · 509 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Bolt Biotherapeutics (BOLT) Bought Dec 5, 2025 · $576 · 125 shares Behind typical Dec 31, 2025 $5.47 → Jun 30, 2026 $3.85 · −29.6% (typical stock +4.7%)
Bolt Biotherapeutics (BOLT) Bought Jun 6, 2025 · $686 · 125 shares Behind typical Jun 30, 2025 $5.77 → Dec 31, 2025 $5.47 · −5.2% (typical stock +2.1%)
Bolt Biotherapeutics (BOLT) Bought Dec 16, 2024 · $1.25K · 2,500 shares Not counted Not counted. We have no fund price for this stock on both Dec 31, 2024 and Jun 30, 2025.
Bolt Biotherapeutics (BOLT) Bought Jun 6, 2024 · $1.6K · 2,500 shares Not counted Not counted. We have no fund price for this stock on both Jun 30, 2024 and Dec 31, 2024.
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.